Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pfizer to co-market Serono's Rebif

PFE paid Serono (SRA; SWX:SEO) $200 million to co-promote in the U.S. Rebif interferon beta-1a to treat multiple sclerosis (MS).

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE